These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25588041)

  • 1. Cell cycle control as a promising target in melanoma.
    Lee B; Sandhu S; McArthur G
    Curr Opin Oncol; 2015 Mar; 27(2):141-50. PubMed ID: 25588041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
    Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
    Sheppard KE; McArthur GA
    Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
    Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
    Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
    [No Abstract]   [Full Text] [Related]  

  • 5. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
    Bachmann IM; Straume O; Akslen LA
    Int J Oncol; 2004 Dec; 25(6):1559-65. PubMed ID: 15547691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
    Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
    J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
    Konecny GE
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell Cycle Regulation and Melanoma.
    Xu W; McArthur G
    Curr Oncol Rep; 2016 Jun; 18(6):34. PubMed ID: 27106898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation testing in melanoma families: INK4A, CDK4 and INK4D.
    Newton Bishop JA; Harland M; Bennett DC; Bataille V; Goldstein AM; Tucker MA; Ponder BA; Cuzick J; Selby P; Bishop DT
    Br J Cancer; 1999 Apr; 80(1-2):295-300. PubMed ID: 10390011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
    Becker TM; Rizos H; Kefford RF; Mann GJ
    Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
    Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genes involved in melanoma: an overview of INK4a and other loci.
    Castellano M; Parmiani G
    Melanoma Res; 1999 Oct; 9(5):421-32. PubMed ID: 10596908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways: CDK4 inhibitors for cancer therapy.
    Dickson MA
    Clin Cancer Res; 2014 Jul; 20(13):3379-83. PubMed ID: 24795392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
    Semczuk A; Miturski R; Skomra D; Jakowicki JA
    Arch Gynecol Obstet; 2004 Jan; 269(2):104-10. PubMed ID: 14648178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function.
    Morris M; Hepburn P; Wynford-Thomas D
    Oncogene; 2002 Jun; 21(27):4277-88. PubMed ID: 12082615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
    McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
    Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
    Phelps DE; Xiong Y
    Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
    Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
    Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.